The diminishing role of transurethral resection of the prostate

Annals of Surgical Oncology

Volumn 17, Issue 5, 2010, Pages 1422-1428

  Merrill, Ray M ^a   Hunter, Bradley D ^a  

^a BRIGHAM YOUNG UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER INCIDENCE; HUMAN; INCIDENTAL FINDING; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY; TRANSURETHRAL RESECTION; TREND STUDY;

AGED; AGED, 80 AND OVER; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; SEER PROGRAM; SURVIVAL RATE; TRANSURETHRAL RESECTION OF PROSTATE; UNITED STATES;

EID: 77952096301     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0896-4     Document Type: Article

References (53)

1. GS Andrews 1949 Latent carcinoma of the prostate J Clin Pathol 2 197 10.1136/jcp.2.3.197
2. CN Edwards E Steinthorsson D Nicholson 1953 An autopsy of latent prostatic cancer Cancer 6 531 10.1002/1097-0142(195305)6:3<531::AID- CNCR2820060311>3.0.CO;2-9 1:STN:280:DyaG3s%2FmslGqtQ%3D%3D 13042777
3. AE Hirst Jr RT Bergman 1954 Carcinoma of the prostate in men 80 or more years old Cancer 7 136 10.1002/1097-0142(195401)7:1<136::AID- CNCR2820070114>3.0.CO;2-C 13126907
4. WF Whitmore Jr 1956 Symposium of hormones and cancer therapy hormone therapy in prostatic cancer Am J Med 21 295
5. R Scott Jr DL Mutchnik TZ Laskowski, et al. 1969 Carcinoma of the prostate in elderly men: Incidence, growth characteristics and clinical significance J Urol 101 602 5776047
6. N Breslow CW Chan G Dhom, et al. 1977 Latent carcinoma of the prostate at autopsy in seven areas Int J Cancer 20 680 688 10.1002/ijc.2910200506 1:STN:280:DyaE1c%2FksFelsg%3D%3D 924691 (Pubitemid 8218533)
7. HB Carter S Piantadosi JT Isaacs 1990 Clinical evidence for and implications of the multistep development of prostate cancer J Urol 143 742 746 1:STN:280:DyaK3c7ovFegtg%3D%3D 2313798 (Pubitemid 20112094)
8. RS Kirby 2000 The natural history of benign prostatic hyperplasia: what have we learned in the last decade? Urology 56 3 6 10.1016/S0090-4295(00)00747-0 1:STN:280:DC%2BD3M%2FjsFKhsQ%3D%3D 11074195
9. EA Platz E Smit GC Curhan, et al. 2002 Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancerprostate surgery in US men Urology 59 877 883 10.1016/S0090-4295(01)01673-9 12031373 (Pubitemid 34522180)
10. P Trueman SC Hood USL Nayak, et al. 1999 Prevalence of lower urinary tract symptoms and self-reported diagnosed "benign prostatic hyperplasia", and their effect on quality of life in a community-based survey of men in the UK BJU Int 83 410 415 10.1046/j.1464-410x.1999.00966.x 1:STN:280:DyaK1M3hvFKiuw%3D%3D 10210562 (Pubitemid 29151164)
11. MJ Barry 1990 Epidemiology and natural history of benign prostatic hyperplasia Urol Clin North Am 17 495 507 1:STN:280:DyaK3czislGqtg%3D%3D 1695778 (Pubitemid 20220193)
12. JM Fitzpatrick 2006 The natural history of benign prostate hyperplasia BJU Int 97 Suppl 2 3 6 10.1111/j.1464-410X.2006.06097.x 16507045 (Pubitemid 43356987)
13. J Geller 1990 Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen J Clin Endocrinol Metab 71 1552 1555 10.1210/jcem-71-6-1552 1:STN:280:DyaK3M%2FjsFykug%3D%3D 1699965 (Pubitemid 120032774)
14. G Crea G Sanfilippo G Anastasi, et al. 2005 Pre-surgical finasteride therapy in patients treated endoscopically for benign prostatic hyperplasia Urol Int 74 51 53 10.1159/000082709 1:CAS:528:DC%2BD2MXht1ymsb0%3D 15711109 (Pubitemid 40868017)
15. Tacklind J, Fink HA, MacDonald R, et al. Finasteride for benign prostatic hyperplasia (Protocol). Cochrane Database Syst Rev. 2009;(3):CD006015.
16. CG Roehrborn P Boyle JC Nickel, et al. 2002 Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia Urology 60 434 441 10.1016/S0090-4295(02)01905-2 12350480 (Pubitemid 35292169)
17. GL Andriole C Roehrborn C Schulman, et al. 2004 Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia Urology 64 537 541 10.1016/j.urology.2004.04.084 1:STN:280: DC%2BD2cvksVGjtw%3D%3D 15351586 (Pubitemid 39200753)
18. CG Roehrborn LS Marks T Fenter, et al. 2005 Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia J Urol 173 515
19. Wilt T, MacDonald R, Hagerty K, et al. Five-alpha-reductase inhibitors for prostate cancer prevention. Cochrane Database Syst Rev. 2008;(2):CD007091. (Pubitemid 351807308)
20. CG Roehrborn P Siami J Barkin, et al. 2008 The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement:2-year results from the CombAT study J Urol 179 616 621 10.1016/j.juro.2007.09.084 1:CAS:528: DC%2BD1cXhvVCmt74%3D 18082216
21. CC Schulman J Cortvriend U Jonas, et al. 1999 Tamsulosin:3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: Analysis of a European, multinational, multicenter, open-label study Eur Urol 36 609 620 10.1159/000020056 1:CAS:528:DyaK1MXotVeqtL4%3D 10559616 (Pubitemid 29516293)
22. H Lepor 1998 Long-term evaluation of tamsulosin in benign prostatic hyperplasia: Placebo-controlled, double-blind extension of phase III trial Urology 51 901 906 10.1016/S0090-4295(98)00127-7 1:STN:280:DyaK1c3ntVOrtQ%3D%3D 9609624 (Pubitemid 28240846)
23. P Abrams CC Schulman S Vaage 1995 Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: A randomized, controlled trial in patients with benign prostatic "obstruction" (symptomatic BPH) Br J Urol 76 325 336 10.1111/j.1464-410X.1995.tb07709.x 1:CAS:528:DyaK2MXoslGrtLk%3D 7551841
24. P Narayan 1998 Tamsulosin: The United States trials Geriatrics 53 S29 S32 9789483 (Pubitemid 28491468)
25. C Chapple KE Andersson 2002 Tamsulosin: An overview World J Urol 19 397 404 1:CAS:528:DC%2BD38XktlWntLk%3D 12022708
26. A Jardin H Bensadoun MC Delauche-Cavallier P Attali 1991 Alfuzosin for treatment of benign prostatic hypertrophy Lancet 337 8755 1457 1461 10.1016/0140-6736(91)93140-5 1:STN:280:DyaK3M3mtVajsA%3D%3D 1710750
27. A Jardin H Bensadoun MC Delauche-Cavallier A Stalla-Bourdillon P Attali 1994 Long-term treatment of benign prostatic hyperplasia with alfuzosin: A 24-30 month survey Br J Urol 74 579 584 10.1111/j.1464-410X.1994.tb09187.x 1:STN:280:DyaK2M7ivVGruw%3D%3D 7530121 (Pubitemid 24348623)
28. CG Roehrborn 2001 Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A randomized, placebo-controlled trial Urology 58 953 959 10.1016/S0090-4295(01)01448-0 1:STN:280:DC%2BD3MnpvV2ntg%3D%3D 11744466 (Pubitemid 34017278)
29. A Jardin H Bensadoun MC Delauche-Cavallier, et al. 1991 Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group Lancet 338 8760 182
30. G Vallancien M Emberton A Alcaraz, et al. 2008 Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: A 3-year experience in real-life practice BJU Int 101 847 852 10.1111/j.1464-410X.2008.07458.x 1:CAS:528:DC%2BD1cXltlOjtLk%3D 18321317 (Pubitemid 351347733)
31. KT McVary 2006 Alfuzosin for symptomatic benign prostatic hyperplasia: Long-term experience J Urol 175 35 42 10.1016/S0022-5347(05)00032-7 1:CAS:528:DC%2BD28XntlWksg%3D%3D 16406865 (Pubitemid 41797080)
32. T Takao A Tsujimura H Kiuchi, et al. 2008 Early efficacy of silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia Int J Urol 15 992 996 18775032
33. K Kawabe M Yoshida Y Homma 2006 Silodosin, a new alpha1A-adrenoceptor- selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men BJU Int 98 1019 1024 10.1111/j.1464-410X.2006.06448.x 1:CAS:528:DC%2BD28Xhtlagu7nN 16945121 (Pubitemid 44536452)
34. LS Marks MC Gittelman LA Hill W Volinn G Hoel 2009 Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: Pooled results of 2 phase 3 studies J Urol 181 2634 2640 10.1016/j.juro.2009.02.034 1:CAS:528:DC%2BD1MXmtV2isLk%3D 19371887
35. RM Merrill EJ Feuer JL Warren, et al. 1999 Role of transurethral resection of the prostate in population-based prostate cancer incidence rates Am J Epidemiol 150 848 860 1:STN:280:DyaK1MvltVCqsw%3D%3D 10522656
36. WJ Catalona DS Smith TL Ratliff, et al. 1993 Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening JAMA 270 948 954 10.1001/jama.270.8.948 1:STN:280:DyaK3szksleruw%3D%3D 7688438 (Pubitemid 23244733)
37. AL Potosky BA Miller PC Albertsen, et al. 1995 The role of increasing detection in the rising incidence of prostate cancer JAMA 273 548 552 10.1001/jama.273.7.548 1:STN:280:DyaK2M7jvFWqtA%3D%3D 7530782
38. RM Merrill AL Potosky EJ Feuer 1996 Changing trends in US prostate cancer incidence rates J Natl Cancer Inst 88 1683 1685 10.1093/jnci/88.22.1683 1:STN:280:DyaK2s%2FosFCktg%3D%3D 8931614 (Pubitemid 26384816)
39. Dennison C, Pokras R. Design and operation of the National Hospital Discharge Survey: 1988 redesign. Vital Health Statistics, Series 1, 2000;39. June 19, 2006. Available at: Http://www.cdc.gov/nchs/data/series/sr-01/sr01-039. pdf. Accessed July 24, 2009.
40. National Center for Health Statistics. National Hospital Discharge Survey Annual Summary, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006 (machine-readable data file and documentation). Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 2007.
41. Ries LAG, Kosary CL, Hankey BF, et al., editors. SEER Cancer Statistics Review, 1973-94. NIH Pub. No. 97-2789. Bethesda, MD: National Cancer Institute; 1997.
42. Centers for Disease Control and Prevention, National Center for Health Statistics. Available at: Http://www.cdc.gov/nchs. Accessed June 12, 2009.
43. Surveillance, Epidemiology, and End Results (SEER) Program SEER Stat Database: Incidence-SEER 13 Regs Limited-Use, Nov 2008 Sub (1992-2006) Katrina/Rita Population Adjustment-Linked to County Attributes-Total US, 1969-2006 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2009, based on the November 2008 submission. Available at: Http://www.seer.cancer.gov. Accessed July 24, 2009.
44. Kleinbaum DG, Kupper LL, Muller KE 1988 Applied Regression Analysis of Other Multivariable Methods. North Scituate, MA: Duxbury Press, pp 266-8.
45. US Department of Health and Human Services. International Classification of Diseases, Ninth Revision. Clinical modification (ICD-9-CM). 3rd ed. DHHS Publication No. (PHS) 89-1260. Hyattsville, MD: US Department of Health and Human Services; 1989.
46. SEER site-specific surgery of primary site codes. Available at: Http://seer.cancer.gov/tools/SEER2003.surg.prim.site.codes.pdf. Accessed June 12, 2009.
47. JS Jones HW Follis JR Johnson 2009 Probability of finding T1a and T1b (incidental) prostate cancer during TURP has decreased in the PSA era Prostate Cancer Prostatic Dis 12 57 60 10.1038/pcan.2008.14 1:STN:280: DC%2BD1M7islyrug%3D%3D 18379587
48. Hoffman RM, Monga M, Elliot SP, et al. Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2007;(4):CD004135. (Pubitemid 351805299)
49. Johns Hopkins guide to BPH. Available at: Http://www. johnshopkinshealthalerts.com/reports/pdfs/BPH-special-report.pdf. Accessed May 27, 2009.
50. Benign prostatic hyperplasia-diagnosis and treatment options at the Mayo Clinic. Available at: Http://www.mayoclinic.org/bph/. Accessed May 27, 2009.
51. P Boyle C Robertson ED Vaughan 2004 A meta-analysis of trials of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia BJU Int 94 83 88 10.1111/j.1464-410X.2004.04906.x 15217437 (Pubitemid 38980314)
52. AL Potosky BA Miller PC Albertsen, et al. 1995 The role of increasing detection in the rising incidence of prostate cancer JAMA 273 548 552 10.1001/jama.273.7.548 1:STN:280:DyaK2M7jvFWqtA%3D%3D 7530782
53. R Etzioni R Gulati S Falcon, et al. 2008 Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: A surveillance modeling approach Med Decis Making 28 323 331 10.1177/0272989X07312719 18319508 (Pubitemid 351713299)